Esperion Reports Completion of Bempedoic Acid in Global P-III LDL-C Development Program for Patients with ASCVD or HeFH

 Esperion Reports Completion of Bempedoic Acid in Global P-III LDL-C Development Program for Patients with ASCVD or HeFH

Esperion Reports Completion of Bempedoic Acid in Global P-III LDL-C Development Program for Patients with ASCVD or HeFH

Shots:

  • The P-III development programs involves five studies assessing Bempedoic Acid (180 mg) (1,2,3,4 study) and bempedoic acid / ezetimibe combination pill vs PBO (053 study) in 4000 patients with ASCVD or HeFH
  • Global P-III results: LDL-C lowering (18% to 31%); Reduction in hsCRP (19% to 33%); Reduction in HbA1c (0.19% to 0.31%); MACE 3/4 /5 (1.9%, 3.8%, 4.0% vs 2.3%, 4.2%, 4.6%); well tolerated and safe
  • Esperion plans to submit NDA to the US FDA & MAA to EMA for bempedoic acid and the bempedoic acid / ezetimibe combination pill in LDL-C patients in Q1’19 & Q2’19 respectively

Click here to read full press release/ article | Ref: Esperion Therapeutics | Image: Investors 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post